Jci_page_head_homepage_01 Jci_page_head_homepage_02
Mingquan Zheng, Alistair J. Ramsay, Myles B. Robichaux, Karen A. Norris, Corrine Kliment, Christopher Crowe, Rekha R. Rapaka, Chad Steele, Florencia McAllister, Judd E. Shellito, Luis Marrero, Paul Schwarzenberger, Qiu Zhong, Jay K. Kolls
Published in Volume 115, Issue 12
J Clin Invest. 2005; 115(12):3536–3544 doi:10.1172/JCI26306
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5

Humoral responses after pKexin or pKexin/CD40L DNA vaccination. (A) Schema of PC Kexin vaccination protocol. DNA vectors used were pKexin, pKexin/CD40L, pBUDCE4 (as empty vector), or pCD40L. (B) Anti-PC IgG1 and IgG2a responses after pKexin or pKexin/CD40L after intramuscular DNA immunization in CD4-depleted and CD4-replete mice. n = 6–8. All data are mean titer ± SEM. *P < 0.05 compared with control. (C) Anti-PC IgG1 and IgG2a responses after pKexin or pKexin/CD40L after intramuscular DNA immunization in CD4–/– and CD4+/+ mice. n = 4–6. All data are mean titer ± SEM. **P < 0.05 compared with CD4+/+ mice or pKexin/CD40L in CD4–/– mice. A line denotes the limit of detection in the ELISA.